Holen Sie sich die Stockscreener-App
0.95
3.06%
-0.0401
Schlusskurs vom Vortag:
$0.9901
Offen:
$0.9801
24-Stunden-Volumen:
82,534
Relative Volume:
0.35
Marktkapitalisierung:
$19.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.76M
KGV:
-0.7364
EPS:
-1.29
Netto-Cashflow:
-
1W Leistung:
-26.17%
1M Leistung:
-12.75%
6M Leistung:
-23.83%
1J Leistung:
+84.65%
1-Tages-Spanne:
$0.9108
$1.0199
1-Wochen-Bereich:
$0.9108
$1.2814
52-Wochen-Spanne:
$0.51
$2.33
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Firmenname
Neurosense Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie NRSN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| NRSN | 0.95 | 19.53M | 0 | -13.76M | 0 | -1.29 |
| VRTX | 449.25 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.22 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.73 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.50 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Neurosense Therapeutics Ltd Aktie (NRSN) Neueste Nachrichten
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND - PR Newswire
NeuroSense to Participate in Upcoming ALS Conferences: PACTALS i - GuruFocus.com
NeuroSense Therapeutics Secures Continued Nasdaq Listing - TipRanks
Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
4 Biotech Stocks With AI, Machine Learning Prowess - Investing.com
NeuroSense Moves Toward Early Commercialization Of ALS Treatment In Canada, Eyeing $100M+ Market - MSN
Neurosense Therapeutics Secures $30 Million Equity Deal - TipRanks
NeuroSense Therapeutics Announces Private Placement with Senior - GuruFocus.com
NeuroSense Completes Key ALS Trial Phase - TipRanks
NeuroSense Therapeutics : INFORMATION CONTAINED IN THIS REPORT ON FORM 6 K Form 6 K - Marketscreener.com
NeuroSense schedules FDA meeting for ALS drug trial - Investing.com India
NeuroSense Therapeutics Advances ALS Drug Development Plans - TipRanks
NeuroSense schedules FDA meeting for ALS drug trial By Investing.com - Investing.com Australia
NeuroSense Therapeutics Ltd. Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission - Marketscreener.com
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission - Nasdaq
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission - Benzinga
NRSNNeuroSense Therapeutics Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
NeuroSense’s PrimeC Shows Potential in ALS Treatment - TipRanks
NeuroSense Therapeutics : New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients Form 6 K - Marketscreener.com
Neurosense Therapeutics Ltd. Announces Transformative Findings from Its Paradigm Clinical Trial of PrimeC - Marketscreener.com
NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market - Nasdaq
NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market | StreetInsider.com - Financial Content
NeuroSense seeks early Canada approval for ALS drug By Investing.com - Investing.com Nigeria
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates - Citizentribune
NeuroSense seeks early Canada approval for ALS drug - Investing.com
NeuroSense Targets Key ALS Drug Market in Canada - TipRanks
NeuroSense Targets Early ALS Drug Approval in Canada - TipRanks
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada - PR Newswire
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting - PR Newswire
NeuroSense Therapeutics Ltd. Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study - Marketscreener.com
XTX Topco Ltd Invests $37,000 in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World
NeuroSense Therapeutics Reports Mid-Year Financials - TipRanks
In the Green: NeuroSense Therapeutics Ltd (NRSN) Closes at 1.25, Up/Down -3.50 from Previous Day - The Dwinnex
NeuroSense extends PrimeC patent protection to 2042 By Investing.com - Investing.com Australia
NeuroSense back in line with Nasdaq bid price rule By Investing.com - Investing.com Australia
NeuroSense back in line with Nasdaq bid price rule - Investing.com
NeuroSense extends PrimeC patent protection to 2042 - Investing.com
NeuroSense Back on Track with NASDAQ Compliance - TipRanks
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's - PR Newswire
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule - PR Newswire
Naspers (OTCMKTS:NPSNY) Share Price Passes Above 50-Day Moving Average of $39.49 - Defense World
SenesTech stock hits 52-week low at $2.4 amid sharp decline - Investing.com
This £300 health scan has a 10k waitlist — I tried it and found out why it's so worth it - Evening Standard
Sachin Tendulkar stock jumps 8% after it gets buy call for an upside of 20% - Trade Brains
Neuralink Blindsight receives FDA Breakthrough Device Designation for visually impaired patients - Shacknews
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Quest Partners LLC Sells 3,065 Shares of Napco Security Technologies, Inc. (NASDAQ:NSSC) - Defense World
Surgery-free Neuralink rival enables thought-controlled smart home - New Atlas
Mind Medicine (MindMed) (NASDAQ:MNMD) Given New $14.00 Price Target at Canaccord Genuity Group - Defense World
NeuroSense Embarks on HIPAA Compliance Journey - TipRanks
Quest Partners LLC Has $298,000 Position in Northern Trust Co. (NASDAQ:NTRS) - Defense World
Finanzdaten der Neurosense Therapeutics Ltd-Aktie (NRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):